Article info
PDFExtended report
Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response
- Dr Ronald F van Vollenhoven, Department of Rheumatology, D2:01, Karolinska University Hospital, Solna, S-171 76 Stockholm, Sweden; ronald.van.vollenhoven{at}ki.se
Citation
Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response
Publication history
- Accepted September 2, 2007
- First published September 7, 2007.
Online issue publication
October 31, 2019
Article Versions
- Previous version (31 October 2019).
- Previous version (31 October 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
2008 BMJ Publishing Group and European League Against Rheumatism